23 July 2025 - Public comment period now open until 19 August 2025; requests to make oral comment during public meeting also being accepted.
The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of brensocatib (Insmed) for non-cystic fibrosis bronchiectasis.